The current PE ratio of CSBR cannot be calculated, as the latest EPS of -$0.05 is negative. The most recent PE ratio recorded for Champions Oncology was 694.0 in October 2022.
Over the last six years, the average PE ratio of Champions Oncology has been 526.5. Looking back at the last six years, CSBR's PE ratio peaked in the Jul 2021 quarter at 1,045, with a price of $10.45 and an EPS of $0.01. The Apr 2022 quarter marked the lowest point at 192, with a price of $7.68 and an EPS of $0.04.
Maximum annual decrease: -46.32% in 2022
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | N/A | N/A | $4.85 | -$0.54 |
2023 | N/A | N/A | $4.92 | -$0.39 |
2022 | 192 | -46.32% | $7.68 | $0.04 |
2021 | 357.67 | N/A | $10.73 | $0.03 |
2020 | N/A | N/A | $7.72 | -$0.18 |
2019 | 908 | N/A | $9.08 | $0.01 |
2018 | N/A | N/A | $4.34 | -$0.13 |
2017 | N/A | N/A | $2.65 | -$0.64 |
2016 | N/A | N/A | $3.85 | -$1.2 |
2015 | N/A | N/A | $7.32 | -$2.2 |
2014 | N/A | N/A | $10.92 | -$1.33 |
2013 | N/A | N/A | $5.28 | -$1.44 |
2012 | N/A | N/A | $8.04 | -$2.28 |
2011 | N/A | N/A | $12 | -$1.32 |
2010 | N/A | N/A | $9.24 | -$1.08 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Oct 2024 | N/A | N/A | $3.91 | -$0.05 |
Jul 2024 | N/A | N/A | $4.79 | -$0.25 |
Apr 2024 | N/A | N/A | $4.85 | -$0.54 |
Jan 2024 | N/A | N/A | $5.81 | -$0.72 |
Oct 2023 | N/A | N/A | $5.46 | -$0.71 |
Jul 2023 | N/A | N/A | $6.5 | -$0.56 |
Apr 2023 | N/A | N/A | $4.92 | -$0.39 |
Jan 2023 | N/A | N/A | $4.11 | -$0.23 |
Oct 2022 | 694 | 140.41% | $6.94 | $0.01 |
Jul 2022 | 288.67 | 50.35% | $8.66 | $0.03 |
Apr 2022 | 192 | -52.12% | $7.68 | $0.04 |
Jan 2022 | 401 | 23.13% | $8.02 | $0.02 |
Oct 2021 | 325.67 | -68.84% | $9.77 | $0.03 |
Jul 2021 | 1,045 | 192.17% | $10.45 | $0.01 |
Apr 2021 | 357.67 | N/A | $10.73 | $0.03 |
Stock name | PE ratio | Market cap |
---|---|---|
EXEL Exelixis Inc | 20.36 | $10.26B |
CRL Charles River Laboratories International Inc | 855.2 | $8.75B |
CLDX Celldex Therapeutics Inc | N/A | $1.36B |
CSBR Champions Oncology Inc | N/A | $127.55M |
The current price to earnings ratio of CSBR cannot be determined, as its EPS of -$0.05 is negative.
The 5-year average price to earnings ratio for CSBR stock is 472.0.
The highest quarterly PE ratio in the last six years has been 1,045 and it was in the Jul 2021 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.